. Assay conditions for MLL family complexes Figure S1 . Optimization of trimeric SET1A and SET1B activity by rotating 30 min with NP40 (final concentration of 0.6%) and 50 U/mL Benzonase Nuclease (Sigma) and 2 mM 2-mercaptoethanol followed by sonication at frequency of 8 (10"on/10"off)
for 4 min (Sonicator 3000, Misoni). The crude extract was clarified by high-speed centrifugation (60 min at 36,000 ×g at 4 o C). The recombinant protein complex was purified by loading the cleared lysate on a Talon metal affinity resin (Clontech) followed by washing with 20 mM TrisHCl, pH 7.5, 500 mM NaCl, 5% glycerol, 15 mM imidazole). The recombinant protein complex was eluted from the cobalt-based affinity column using the elution buffer (20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 5% glycerol, 250 mM imidazole). The eluate with 3 mM 2-mercaptoethanol and 1X Roche complete EDTA-free protease inhibitor was concentrated and loaded onto a gel filtration Superdex-200 column (GE Healthcare) and eluted with sodium phosphate buffer (50 mM, pH 7.0), 150 mM NaCl and 5 mM 2-Mercaptoethanol. The pure fractions (as judged by SDS-PAGE) were pooled, concentrated, and flash frozen.
Recombinant DPY-30 was overexpressed as a polyhistidine fusion protein in E. coli BL21 (DE3)-V2R-pRARE2 by addition of 1 mM IPTG and incubated overnight at 15 ˚C. Harvested cells were resuspended in 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 5 mM imidazole, and 5%
glycerol, supplemented with 1X protease inhibitor cocktail (100X protease inhibitor stock in 70% ethanol (0.25 mg/ml Aprotinin, 0.25 mg/ml Leupeptin, 0.25 mg/ml Pepstatin A and 0.25 mg/ml E-64) or 1X Complete EDTA-free protease inhibitor cocktail tablet (Roche Applied Science, Penzberg, Germany). Cells were chemically lysed by rotating for 30 min with 0.5% CHAPS and 22.5 U/mL Benzonase nuclease followed by sonication at frequency of 8.5 with a 50% duty cycle for 4 min (Sonicator 3000, Misoni). The crude extract was clarified by highspeed centrifugation (60 min at 36,000 ×g at 4 o C) and the resulting clarified lysate was loaded onto a DE52 ion-exchange resin (GE Healthcare Life Sciences) and passed through a Hispur TM Ni-NTA resin (Thermo Scientific) column. The column was washed with 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 5% glycerol, 30 mM imidazole and retained protein was eluted in the same buffer containing 250 mM imidazole. Purified DPY30 was dialyzed against 50 mM sodium phosphate pH 7.0, 150 mM NaCl and 5 mM 2-Mercaptoethanol and concentrated for storage.
Purity was confirmed by SDS-PAGE and LC-MS.
SET domains of SET1A and SET1B were overexpressed as His-SUMO fusion in E. MLL complexes were formed immediately after purification of the SET domain by mixing the desired protein members in equimolar ratios during a 2-hour dialysis at 4 o C against Bis-tris propane (20 mM, pH 7.0), 250 mM NaCl and 5 mM 2-mercaptoethanol. The complexes were concentrated and purified over a Superdex-200 16/60 size exclusion column in the same buffer.
Complex order and purity was determined using SDS-PAGE analysis.
Histone methyltransferase assays
Histone methyltransferase assays were performed in an assay buffer consisting of 20 mM TrisHCl pH 8.0, 0.01% Triton X-100, and 5 mM DTT. All MLL complexes were desalted using *Concentration of SET domain of SET1A and SET1B within the trimeric complex was increased to molar ratio of 4:1.
While trimeric SET1A and SET1B eluted from the gel filtration column as a complex, no activity was observed with the peptide substrate. However, increasing SET domain / WDR5-RbBP5 ratio to 4:1 instead of 1:1 resulted in active trimeric complex. For these experiments, 500
nM of the trimeric complex was mixed with various amounts of additional purified SET domain for 10 minutes at room temperature before performing activity assays. SET1A reactions were performed for 60 minutes in the presence of 500 µM SAM and 100 µM H3 1-25 biotin peptide, while SET1B reactions were performed for 60 minutes in the presence of 50 µM SAM and 25 µM H3 1-25 biotin peptide. Incorporated radioactivity was quantified using biotin capture membranes as described above. It was determined that maximal activity for trimeric complexes was obtained at a 4x molar ratio of SET domain to previously prepared trimeric complex and this mixture was used for the determination of kinetic parameters.
Kinetic constants were calculated using nonlinear least squares regression analysis in GraphPad Prism v. 6.03 using the Michaelis-Menten model. For instances in which regression analysis 6 produced unreliable fits, the data are reported as greater than the highest concentration of substrate utilized in the experiment. Figure S1 . Optimization of trimeric SET1A and SET1B activity by increasing SET domain to WDR5-RbBP5 ratio. A) Trimeric SET1A (500 nM) was incubated with increasing amounts of additional SET1A SET domain before determination of methyltransferase activity as described in Materials and Methods. The molar ratios of SET1A SET domain to WDR5-RbBP5 complex are as follows: 0 (1:1), 1 (1:2), 2 (1:3) and 3 (1:4). B) Trimeric SET1B (500 nM) was also incubated with increasing amounts of additional SET1B SET domain before determination of methyltransferase activity. The molar ratios of SET1B SET domain to WDR5-RbBP5 complex are as follows: 0 (1:1), 1 (1:2), 2 (1:3), 3 (1:4) and 4 (1:5). Control (C) is 1500 nM of SET1A and SET1B alone. Table 1 . Data are presented as the mean ± SD from three independent experiments. Table 1 . Data are presented as the mean ± SD from three independent experiments. Table 1 . Data are presented as the mean ± SD from three independent experiments. Table 1 . Data are presented as the mean ± SD from three independent experiments. The effects of sodium chloride (NaCl) on activity of pentameric complexes of MLL1, MLL3, SET1A, and SET1B were evaluated. NaCl at concentrations as low as 10 mM significantly reduced the activity of all four pentameric complexes as specified. pH profile for each enzyme was determined B) in the absence and C) presence of 0.01% Triton X-100. 
